Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma

被引:3
|
作者
Garderet, Laurent
Mazurier, Christelle
Pellat-Deceunynck, Catherine
Karim, Abdul
Baudin, Bruno
Funck-Brentano, Christian
Bouchet, Sandrine
Geffroy, Alexandrine
Bataille, Regis
Gorin, Norbert-Claude
Lopez, Manuel
机构
[1] Univ Paris 06, Fac Med St Antoine, INSERM, Serv Hematol, F-75012 Paris, France
[2] Univ Paris 06, Fac Med St Antoine, EA1638, F-75012 Paris, France
[3] Hop St Antoine, Dept Haematol & Cell Therapy, F-75571 Paris, France
[4] U601, Nantes, France
[5] EFS Ile de France, Versailles, France
[6] Hop St Antoine, Dept Biochem, F-75571 Paris, France
[7] Hop St Antoine, Ctr Invest Clin, Paris, France
关键词
dendritic cell; T-cells; myeloma cell; idiotype; tumor lysate;
D O I
10.1080/10428190500465242
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study evaluated the feasibility of using dendritic cells (DCs) to generate, ex vivo, anti-tumor cytotoxic T lymphocytes (CTL) in patients with stage III multiple myeloma ( MM). Nucleated cells from eight patients who had received chemotherapy ( three of whom had undergone autologous hemopoeitic stem cell transplantation) were collected by apheresis. Their monocytes were enriched using counter-current centrifugation, differentiated into DCs which were further co-cultured with autologous CD8 lymphocytes to induce CTL. The DCs were pulsed either with the idiotypic paraprotein ( regarded as a tumor-specific antigen) or with autologous MM cell lysate before co-culture. Specific T-cell responses were measured in IFN gamma enzyme-linked immunospot and chromium release assays of autologous plasmocyte targets. A slight increase in IFNg secretion by T-cells was observed for two patients ( DCs pulsed with idiotypic paraprotein for one, MM cell lysate for the other). No or weak specific lysis of plasmocyte targets was observed in the chromium release assays. In conclusion, the T-cell response to pulsed DCs was very weak or absent. There are clinical and technical reasons that could explain, in part, this lack of response.
引用
收藏
页码:1340 / 1347
页数:8
相关论文
共 50 条
  • [31] Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma
    Gatza, E
    Okada, CY
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 169 (09): : 5227 - 5235
  • [32] Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma
    Bachleitner-Hofmann, Thomas
    Strohschneider, Michaela
    Krieger, Peter
    Sachet, Monika
    Dubsky, Peter
    Hayden, Hubert
    Schoppmann, Sebastian F.
    Pfragner, Roswitha
    Gnant, Michael
    Friedl, Josef
    Stift, Anton
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11): : 4571 - 4577
  • [33] Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Gastric and Colorectal Cancer Patients
    Gao, Daiqing
    Li, Changyou
    Xie, Xihe
    Zhao, Peng
    Wei, Xiaofang
    Sun, Weihong
    Liu, Hsin-Chen
    Alexandrou, Aris T.
    Jones, Jennifer
    Zhao, Ronghua
    Li, Jian Jian
    [J]. PLOS ONE, 2014, 9 (04):
  • [34] Induction of Cellular Immune Responses in Patients With Stage-I Multiple Myeloma After Vaccination With Autologous Idiotype-pulsed Dendritic Cells
    Roellig, Christoph
    Schmidt, Christian
    Bornhaeuser, Martin
    Ehninger, Gerhard
    Schmitz, Marc
    Auffermann-Gretzinger, Susanne
    [J]. JOURNAL OF IMMUNOTHERAPY, 2011, 34 (01) : 100 - 106
  • [35] Ex Vivo Induction of Multiple Myeloma-specific Immune Responses by Monocyte-derived Dendritic Cells Following Stimulation by Whole-tumor Antigen of Autologous Myeloma Cells
    Vasileiou, Spyridoula
    Baltadakis, Ioannis
    Delimpasi, Sosanna
    Karatza, Maria-Helena
    Liapis, Konstantinos
    Garofalaki, Maria
    Tziotziou, Eirini
    Poulopoulog, Zoe
    Karakasis, Dimitri
    Harhalakis, Nicholas
    [J]. JOURNAL OF IMMUNOTHERAPY, 2017, 40 (07) : 253 - 264
  • [36] Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study
    Lau, S. P.
    Klaase, L.
    Vink, M.
    Dumas, J.
    Bezemer, K.
    van Krimpen, A.
    van der Breggen, R.
    Wismans, L. V.
    Doukas, M.
    de Koning, W.
    Stubbs, A. P.
    Mustafa, D. A. M.
    Vroman, H.
    Stadhouders, R.
    Nunes, J. B.
    Stingl, C.
    de Miranda, N. F. C. C.
    Luider, T. M.
    Burg, S. H. van der
    Aerts, J. G.
    van Eijck, C. H. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 169 : 20 - 31
  • [37] Modulation of anti-tumor T-cell responses ex vivo by human dendritic cells (DC) fed with apoptotic tumor cells (ATC)
    Meidenbauer, HN
    Dworacki, G
    Watkins, S
    DeLeo, A
    Whiteside, TL
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 114 (01) : 217 - 217
  • [38] Induction of cytomegalovirus pp65-specific CD8+T Cells in vivo following administration of autologous tumor lysate-pulsed dendritic cells, co-pulsed with zoledronate and a-galactosylceramide in glioblastoma multiforme patient
    Deng, X.
    Nieda, M.
    Eiraku, Y.
    Yagi, M.
    Terunuma, H.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1789 - 1789
  • [39] Analysis of dendritic (DC) and T cell functions in myeloma patients: Response of autologous T cells to idiotype protein (Id)-pulsed DCs in vitro.
    Schuett, P
    Buttkereit, U
    Brandhorst, D
    Lindemann, M
    Schmiedl, S
    Opalka, B
    Hans, GW
    Siegfried, S
    Nowrousian, MR
    Moritz, T
    [J]. BLOOD, 2003, 102 (11) : 931A - 932A
  • [40] A new immunotherapeutic approach for advanced renal cell cancer with tumor lysate pulsed interleukin-12 secreting autologous dendritic cells
    Wimpissinger, F.
    Felzmann, T.
    Huegel, H.
    Funovics, P.
    Stackl, W.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (14) : 803 - 803